PRESS RELEASE published on 03/04/2026 at 22:30, 7 months 24 days ago DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies to participate in upcoming investor conferences to present its late-stage biopharmaceutical developments for food allergies. Company uses proprietary VIASKIN patch technology for treatment Investor Conferences Biopharmaceutical DBV Technologies Food Allergies VIASKIN Patch
BRIEF published on 03/03/2026 at 22:35, 7 months 25 days ago DBV Technologies: February 2026 Voting Rights and Shares Update Voting Rights Shares DBV Technologies NYSE Euronext Paris February 2026
BRIEF published on 03/03/2026 at 22:35, 7 months 25 days ago DBV Technologies: Update on voting rights and shares Euronext Paris Share Capital Voting Rights Financial Regulations DBV Technologies
PRESS RELEASE published on 03/03/2026 at 22:30, 7 months 25 days ago Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 Important update on total voting rights and shares as of February 28, 2026 for NYSE Euronext Paris. Total gross voting rights: 278,352,082 Shares Total Voting Rights Regulations NYSE Euronext Paris February 28 2026
BRIEF published on 03/02/2026 at 15:53, 7 months 26 days ago JP Morgan's investment in DBV Technologies reaches new thresholds Crossing Thresholds Equity Swaps Shares And Voting Rights DBV Technologies JP Morgan
BRIEF published on 02/28/2026 at 20:30, 8 months ago DBV Technologies Unveils Promising Phase 3 VITESSE Study Results at AAAAI 2026 DBV Technologies Phase 3 Results Viaskin Peanut Patch Peanut Allergy Treatment VITESSE Study
BRIEF published on 02/28/2026 at 20:30, 8 months ago DBV Technologies reveals promising new results for VIASKIN Peanut Clinical Study Immunotherapy DBV Technologies Food Allergies Viaskin Peanut
PRESS RELEASE published on 02/28/2026 at 20:25, 8 months ago DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting DBV Technologies presents successful Phase 3 VITESSE study data at AAAAI Annual Meeting, highlighting VIASKIN Peanut Patch efficacy in treating peanut-allergic children DBV Technologies Food Allergies Viaskin Peanut Patch Phase 3 VITESSE Study AAAAI Annual Meeting
BRIEF published on 02/09/2026 at 22:35, 8 months 19 days ago DBV Technologies at the Emerging Outlook: Biotech Summit conference Immunotherapy DBV Technologies Viaskin Food Allergies Biotech Summit
BRIEF published on 02/09/2026 at 22:35, 8 months 19 days ago DBV Technologies to Join Guggenheim Biotech Summit Biopharmaceutical DBV Technologies Food Allergies VIASKIN® Patch Guggenheim Securities Summit
Published on 10/28/2026 at 22:35, 1 hour 38 minutes ago Route1 Announces Third Quarter and Year to Date 2026 Financial Results Notification
Published on 10/28/2026 at 12:30, 11 hours 43 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 11 hours 43 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 11 hours 43 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 11 hours 43 minutes ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/28/2026 at 21:35, 2 hours 38 minutes ago Food & Beverage Manufacturers Race to Scale AI Beyond the Pilot Stage
Published on 10/28/2026 at 21:15, 2 hours 58 minutes ago Amrize Completes $1 Billion Share Repurchase Program
Published on 10/28/2026 at 20:36, 3 hours 37 minutes ago Vonovia’s Core Business Remains Resilient as Higher Financing Costs and Weaker Transaction Business Shape 2027 Guidance and 2028 Objectives
Published on 10/28/2026 at 20:35, 3 hours 38 minutes ago EQS-Adhoc: Vonovia specifies Guidance for 2026 and adjusts Guidance for Organic Rent Growth and Operating Free Cash Flow for 2026; Publication of initial 2027 Guidance and revision of 2028 Objectives
Published on 10/28/2026 at 17:45, 6 hours 28 minutes ago VOGO obtains FIBA (International Basketball Federation) Approval for its Instant Replay System.
Published on 10/28/2026 at 17:45, 6 hours 28 minutes ago Successful issue of a € 6.0 billion bond as part of the financing of the PTC acquisition
Published on 10/28/2026 at 17:45, 6 hours 28 minutes ago Groupe CRIT : Revenue over 9 months 2026 : €2.55 billion (+2.2% organic growth).
Published on 10/28/2026 at 17:45, 6 hours 28 minutes ago Infotel : Acceleration of growth in Q3 2026: €77.9m (+11.3%). Confirmation of growth and profitability targets for 2026 as a whole.
